Blog
RSS FeedPosted by Michael Wonder on 21 Jan 2025
Immunotherapy Qarziba to be reimbursed for high-risk neuroblastoma patients starting next month
28 November 2024 - The treatment landscape for neuroblastoma, the most common cancer in children outside of blood and brain ...
Posted by Michael Wonder on 20 Jan 2025
Handok's AML treatment Vyxeos receives insurance coverage in Korea
2 December 2024 - Handok said Monday that its acute myeloid leukaemia treatment, Vyxeos liposomal injection (cytosine arabinoside and daunorubicin ...
Posted by Michael Wonder on 08 Jan 2025
Korea's only RET inhibitor, Retevmo, seeks insurance coverage again
6 January 2025 - Lilly Korea is again pursuing reimbursement for Retevmo (selpercatinib), the only RET inhibitor in Korea. ...
Posted by Michael Wonder on 12 Dec 2024
Merck's Tepmetko, GSK-Janssen's Vocabria+Rekambys combo move closer to reimbursement in Korea
6 December 2024 - Merck's MET inhibitor Tepmetko (tepotinib) has been recognized by the national health insurance reviewer as eligible ...
Posted by Michael Wonder on 02 Dec 2024
Gilead’s Trodelvy awaits re-deliberation for reimbursement in Korea following patient petitions, price cut proposal
25 November 2024 - The triple negative breast cancer treatment Trodelvy (sacituzumab govitecan), which drew 100,000 petitions from patients, will ...
Posted by Michael Wonder on 02 Nov 2024
Handok's rare blood disorder treatment Empaveli wins insurance coverage
1 November 2024 - Starting today, Handok's Empaveli (pegcetacoplan), a treatment for paroxysmal nocturnal haemoglobinuria, will be covered by Korean ...
Posted by Michael Wonder on 21 Oct 2024
Drug price negotiations for obstructive hypertrophic cardiomyopathy drug Camzyos stall, delaying reimbursement
21 October 2024 - Urgent attention is on the drug price negotiations for the obstructive hypertrophic cardiomyopathy (oHCM) treatment Camzyos ...
Posted by Michael Wonder on 10 Oct 2024
Pulmonary fibrosis drug Ofev nears key reimbursement decision in Korea
10 October 2024 - The Pharmaceutical Reimbursement Evaluation Committee under HIRA is reportedly set to review Ofev (nintedanib), a treatment ...
Posted by Michael Wonder on 05 Sep 2024
Tevimbra and Pemazyre pass cancer panel after rechallenge
29 August 2024 - BeiGene's anti-PD-1 immuno-oncology drug Tevimbra (tislelizumab) and Handok's FGFR inhibitor Pemazyre (pemigatinib) have passed the Cancer ...
Posted by Michael Wonder on 13 Aug 2024
Government, Lilly Korea turn a blind eye to Retevmo’s prohibitive cost
12 August 2024 - Patients are appealing to the government to cover the cost of Lilly Korea's Retevmo (selpercatinib), the ...
Posted by Michael Wonder on 08 Jul 2024
Besremi retries for insurance coverage promising a potential operational cure
8 July 2024 - Besremi (rofeginterferon alfa-2b), which has recently set a new standard in treating polycythemia vera by offering ...
Posted by Michael Wonder on 03 Jul 2024
CSL Behring’s haemophilia B drug Idelvion gets insurance coverage
2 July 2024 - CSL Behring's long-acting hemophilia B treatment Idelvion (albutrepenonacog alfa) has come to receive reimbursement in Korea. ...
Posted by Michael Wonder on 01 Jul 2024
Antengene announces Xpovio (selinexor) National Health Insurance Service approval for reimbursement in South Korea
26 June 2024 - The approval of Xpovio by the NHIS in South Korea is the fourth national reimbursement in the ...
Posted by Michael Wonder on 25 Jun 2024
Will Trodelvy get innovative new drug status backed by 100,000 petitions?
24 June 2024 - As the government will likely reflect innovative new drug values on its reimbursement criteria this year, ...
Posted by Michael Wonder on 15 Jun 2024
Extremely rare disease drug Ceprotin clears major hurdle to reimbursement
14 June 2024 - Ceprotin (protein C concentrate), an ultra-rare disease treatment developed by Takeda Pharmaceutical Korea, has passed the ...